Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
FDA Approval of Intragastric Balloon System
Device assists adults with weight management
Indications: The ORBERA Intragastric Balloon System is indicated for adult obese patients who have a body mass index (BMI) of 30 to 40 kg/m2 who have been unable to lose weight through diet and exercise.
Mechanism of action: The temporary system is placed into the stomach through the mouth, helps patients lose weight and should be removed after 6 months.
Efficacy and safety: In a clinical trial, 255 patients who used the system lost an average of 22 pounds. The device should not be used in patients who already have an intragastric balloon, have had prior gastrointestinal or bariatric surgery, or have any inflammatory disease of the GI tract.
Citation: FDA website. ORBERA intragastric balloon system. http://www.fda.gov/medicaldevices/productsandmedicalprocedures/deviceapp.... Updated August 6, 2015. Accessed August 11, 2015.
This Week's Must Reads
Antibiotic Use Among US Older Adults, BMJ; ePub 2018 Jul 27; Olesen, Barnett, et al
Healthy Behaviors & Reduced Risk of Obesity , Mayo Clin Proc; ePub 2018 Jul 27; Shook, et al
Modifiable Risk Factors in New BP Categories, Am J Med; ePub 2018 Jul 26; Gu, Yue, et al
Psychological Screening for Youth with Abdominal Pain, Pediatrics; ePub 2018 Jul 25; Cunningham, et al
Low-Calorie Sweetened Beverages & Cardiometabolic Health, Circulation; ePub 2018 Jul 30; Johnson, et al
Must Reads in Obesity
Healthy Behaviors & Reduced Risk of Obesity , Mayo Clin Proc; ePub 2018 Jul 27; Shook, et al
Healthy Lifestyle & Lower Risk of Obesity in Offspring, BMJ; ePub 2018 Jul 4; Dhana, Haines, et al
Obesity Prevalence Among US Adults, JAMA; 2018 Jun 19; Hales, Fryar, et al
Sleep Insufficiency’s Role in Childhood Obesity, Sleep Medicine; ePub 2018 Apr 5; Arora, et al
Impact of Intensive Weight Loss & Life Expectancy, Diabetes Care; ePub 2018 Mar 15; Gregg, et al